Teprotumumab-trbw (Tepezza)

Covered only for the FDA‑approved treatment of thyroid eye disease in adults ≥18 with active, at least moderate severity disease (off‑label/non‑FDA uses are excluded). Approval requires prescription by or consultation with an ophthalmologist, endocrinologist, or physician specializing in thyroid eye disease, documentation of diagnosis/severity/age, adherence to the dosing schedule (10 mg/kg IV initial, then 20 mg/kg IV every 3 weeks for 7 additional infusions), and is granted for 6 months.

"Tepezza is indicated for the treatment of thyroid eye disease."

Sign up to see full coverage criteria, indications, and limitations.